Protalix Cash And Cash Equivalents Changes vs Begin Period Cash Flow Analysis

PLX Stock

USD 1.69 0.01 0.60%

Protalix Biotherapeutics financial indicator trend analysis is much more than just breaking down Protalix Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protalix Biotherapeutics is a good investment. Please check the relationship between Protalix Biotherapeutics Cash And Cash Equivalents Changes and its Begin Period Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Cash And Cash Equivalents Changes vs Begin Period Cash Flow

Cash And Cash Equivalents Changes vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protalix Biotherapeutics Cash And Cash Equivalents Changes account and Begin Period Cash Flow. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Protalix Biotherapeutics' Cash And Cash Equivalents Changes and Begin Period Cash Flow is -0.36. Overlapping area represents the amount of variation of Cash And Cash Equivalents Changes that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Protalix Biotherapeutics, assuming nothing else is changed. The correlation between historical values of Protalix Biotherapeutics' Cash And Cash Equivalents Changes and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Cash Equivalents Changes of Protalix Biotherapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Cash And Cash Equivalents Changes i.e., Protalix Biotherapeutics' Cash And Cash Equivalents Changes and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.36

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash And Cash Equivalents Changes

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Protalix Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 287.5 K in 2024, despite the fact that Discontinued Operations is likely to grow to (206.5 K).

	2021	2022	2023	2024 (projected)
Total Revenue	38.4M	47.6M	65.5M	68.8M
Depreciation And Amortization	1.1M	1.1M	1.2M	1.7M

Total Revenue Depreciation And Amortization

Protalix Biotherapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Non Currrent Assets Other	Common Stock Total Equity	Other Stockholder Equity	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Other Assets	Other Liab
Total Assets		0.04	0.19	-0.24	0.85	0.57	0.95	-0.03	0.0	0.45	-0.64	0.62	0.99	0.6	0.04	0.46	-0.22	-0.16	0.5	0.41	0.49	0.56	0.09	0.02	0.38	0.23
Other Current Liab	0.04		0.44	0.16	-0.22	0.33	-0.12	0.52	0.49	-0.27	-0.24	-0.02	-0.02	-0.03	0.13	0.34	-0.39	0.12	-0.43	0.26	0.29	-0.39	0.14	0.49	-0.28	-0.1
Total Current Liabilities	0.19	0.44		0.56	-0.1	0.19	0.09	0.05	0.39	-0.43	-0.47	0.16	0.18	0.3	0.02	0.13	-0.56	-0.2	-0.1	0.35	0.65	-0.08	0.15	0.42	-0.27	-0.35
Net Debt	-0.24	0.16	0.56		-0.38	-0.36	-0.29	0.13	0.15	-0.19	-0.35	0.14	-0.19	-0.04	-0.35	-0.44	-0.45	-0.31	-0.3	0.32	0.16	-0.31	-0.1	0.15	-0.08	-0.58
Cash	0.85	-0.22	-0.1	-0.38		0.34	0.95	-0.32	-0.31	0.63	-0.41	0.62	0.87	0.67	-0.05	0.31	0.15	-0.12	0.69	0.15	0.36	0.66	-0.05	-0.27	0.56	0.34
Non Current Assets Total	0.57	0.33	0.19	-0.36	0.34		0.41	0.42	0.05	0.31	-0.28	0.46	0.43	0.59	-0.11	0.97	-0.25	0.47	0.18	0.22	0.24	0.22	0.67	0.01	0.2	0.6
Cash And Short Term Investments	0.95	-0.12	0.09	-0.29	0.95	0.41		-0.27	-0.16	0.5	-0.5	0.6	0.96	0.65	0.05	0.34	0.02	-0.18	0.62	0.26	0.5	0.63	-0.04	-0.14	0.39	0.24
Net Receivables	-0.03	0.52	0.05	0.13	-0.32	0.42	-0.27		0.46	0.04	-0.29	0.07	-0.12	-0.08	-0.11	0.36	-0.62	0.36	-0.13	0.39	-0.27	-0.02	0.54	0.22	0.03	0.11
Common Stock Shares Outstanding	0.0	0.49	0.39	0.15	-0.31	0.05	-0.16	0.46		-0.57	-0.4	-0.37	0.0	-0.34	0.61	0.04	-0.7	-0.25	-0.33	0.65	0.0	-0.2	-0.04	0.72	-0.5	-0.49
Non Current Liabilities Total	0.45	-0.27	-0.43	-0.19	0.63	0.31	0.5	0.04	-0.57		-0.23	0.82	0.43	0.5	-0.68	0.27	0.11	0.11	0.55	0.02	-0.08	0.49	0.19	-0.51	0.78	0.69
Other Current Assets	-0.64	-0.24	-0.47	-0.35	-0.41	-0.28	-0.5	-0.29	-0.4	-0.23		-0.55	-0.65	-0.36	0.08	-0.15	0.76	0.5	-0.17	-0.72	-0.28	-0.25	-0.01	-0.27	-0.37	0.2
Total Liab	0.62	-0.02	0.16	0.14	0.62	0.46	0.6	0.07	-0.37	0.82	-0.55		0.59	0.75	-0.72	0.38	-0.24	-0.01	0.53	0.25	0.32	0.49	0.31	-0.29	0.68	0.53
Total Current Assets	0.99	-0.02	0.18	-0.19	0.87	0.43	0.96	-0.12	0.0	0.43	-0.65	0.59		0.54	0.07	0.32	-0.19	-0.27	0.52	0.41	0.49	0.57	-0.03	0.03	0.38	0.13
Short Long Term Debt Total	0.6	-0.03	0.3	-0.04	0.67	0.59	0.65	-0.08	-0.34	0.5	-0.36	0.75	0.54		-0.37	0.59	-0.04	0.22	0.62	0.18	0.4	0.54	0.39	-0.35	0.44	0.44
Total Stockholder Equity	0.04	0.13	0.02	-0.35	-0.05	-0.11	0.05	-0.11	0.61	-0.68	0.08	-0.72	0.07	-0.37		-0.06	0.03	-0.17	-0.22	0.15	0.04	-0.13	-0.33	0.45	-0.6	-0.49
Property Plant And Equipment Net	0.46	0.34	0.13	-0.44	0.31	0.97	0.34	0.36	0.04	0.27	-0.15	0.38	0.32	0.59	-0.06		-0.14	0.53	0.15	0.13	0.22	0.16	0.67	-0.02	0.13	0.63
Retained Earnings	-0.22	-0.39	-0.56	-0.45	0.15	-0.25	0.02	-0.62	-0.7	0.11	0.76	-0.24	-0.19	-0.04	0.03	-0.14		0.25	0.07	-0.79	-0.03	-0.04	-0.3	-0.57	-0.05	0.25
Non Currrent Assets Other	-0.16	0.12	-0.2	-0.31	-0.12	0.47	-0.18	0.36	-0.25	0.11	0.5	-0.01	-0.27	0.22	-0.17	0.53	0.25		0.1	-0.33	-0.06	0.07	0.76	-0.18	0.02	0.51
Common Stock Total Equity	0.5	-0.43	-0.1	-0.3	0.69	0.18	0.62	-0.13	-0.33	0.55	-0.17	0.53	0.52	0.62	-0.22	0.15	0.07	0.1		0.08	0.08	0.98	0.16	-0.44	0.48	0.46
Other Stockholder Equity	0.41	0.26	0.35	0.32	0.15	0.22	0.26	0.39	0.65	0.02	-0.72	0.25	0.41	0.18	0.15	0.13	-0.79	-0.33	0.08		-0.07	0.18	0.03	0.47	0.05	-0.29
Short Term Debt	0.49	0.29	0.65	0.16	0.36	0.24	0.5	-0.27	0.0	-0.08	-0.28	0.32	0.49	0.4	0.04	0.22	-0.03	-0.06	0.08	-0.07		0.07	0.04	0.07	-0.19	-0.05
Common Stock	0.56	-0.39	-0.08	-0.31	0.66	0.22	0.63	-0.02	-0.2	0.49	-0.25	0.49	0.57	0.54	-0.13	0.16	-0.04	0.07	0.98	0.18	0.07		0.16	-0.36	0.45	0.4
Accounts Payable	0.09	0.14	0.15	-0.1	-0.05	0.67	-0.04	0.54	-0.04	0.19	-0.01	0.31	-0.03	0.39	-0.33	0.67	-0.3	0.76	0.16	0.03	0.04	0.16		0.08	0.22	0.5
Short Term Investments	0.02	0.49	0.42	0.15	-0.27	0.01	-0.14	0.22	0.72	-0.51	-0.27	-0.29	0.03	-0.35	0.45	-0.02	-0.57	-0.18	-0.44	0.47	0.07	-0.36	0.08		-0.31	-0.42
Other Assets	0.38	-0.28	-0.27	-0.08	0.56	0.2	0.39	0.03	-0.5	0.78	-0.37	0.68	0.38	0.44	-0.6	0.13	-0.05	0.02	0.48	0.05	-0.19	0.45	0.22	-0.31		0.41
Other Liab	0.23	-0.1	-0.35	-0.58	0.34	0.6	0.24	0.11	-0.49	0.69	0.2	0.53	0.13	0.44	-0.49	0.63	0.25	0.51	0.46	-0.29	-0.05	0.4	0.5	-0.42	0.41

Click cells to compare fundamentals

Protalix Biotherapeutics Account Relationship Matchups

Protalix Biotherapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	45.4M	67.9M	73.7M	55.8M	84.4M	51.0M
Other Current Liab	11.9M	13.9M	15.2M	10.6M	15.3M	16.0M
Total Current Liabilities	40.2M	86.5M	33.2M	32.4M	45.5M	47.8M
Net Debt	43.1M	46.1M	(5.5M)	16.4M	2.6M	2.8M
Cash	17.8M	18.3M	39.0M	17.1M	23.6M	31.8M
Non Current Assets Total	12.9M	12.2M	12.0M	10.9M	14.5M	9.6M
Cash And Short Term Investments	17.8M	38.5M	39.0M	22.2M	44.6M	33.7M
Net Receivables	4.7M	2M	3.4M	4.6M	5.3M	3.1M
Common Stock Shares Outstanding	14.8M	29.1M	44.1M	48.5M	82.4M	86.5M
Liabilities And Stockholders Equity	45.4M	67.9M	73.7M	55.8M	84.4M	51.0M
Non Current Liabilities Total	75.5M	8.5M	46.5M	34.0M	5.3M	5.1M
Other Current Assets	698K	2.1M	1.3M	1.3M	1.1M	1.6M
Total Liab	115.7M	95.0M	79.7M	66.4M	50.9M	56.1M
Total Current Assets	32.5M	55.7M	61.7M	44.9M	69.9M	42.5M
Short Long Term Debt Total	60.9M	64.4M	33.5M	33.5M	26.3M	51.9M
Total Stockholder Equity	(70.3M)	(27.0M)	(6.0M)	(10.6M)	33.6M	35.2M
Property Plant And Equipment Net	11.0M	10.4M	9.9M	9.6M	10.9M	10.5M
Retained Earnings	(340.8M)	(347.4M)	(374.9M)	(389.9M)	(381.5M)	(362.5M)
Non Currrent Assets Other	2.0M	1.8M	2.1M	1.3M	528K	501.6K
Common Stock Total Equity	144K	148K	15K	35K	40.3K	62.7K
Other Stockholder Equity	270.5M	320.3M	368.9M	379.2M	415.0M	435.8M
Short Term Debt	5.4M	59.9M	2.4M	2.2M	23.1M	18.6M
Common Stock	15K	35K	46K	54K	73K	62.8K
Accounts Payable	6.5M	7.2M	7.0M	5.9M	4.3M	4.3M
Short Term Investments	26K	20.3M	39.0M	5.1M	20.9M	22.0M
Other Assets	2.0M	7.4K	2.1M	1.3M	1.0	0.95
Other Liab	20.1M	4.0M	14.3M	1.6M	1.5M	1.4M
Property Plant Equipment	5.3M	10.4M	9.9M	9.6M	8.7M	8.1M
Current Deferred Revenue	16.3M	5.4M	8.6M	13.2M	2.9M	2.7M
Inventory	8.2M	13.1M	18.0M	16.8M	19.0M	9.6M
Net Tangible Assets	(70.3M)	(27.0M)	(6.0M)	(10.6M)	(9.6M)	(10.1M)
Long Term Debt	51.0M	51K	27.9M	28.2M	25.4M	28.8M
Capital Surpluse	270.5M	320.3M	368.9M	379.2M	436.0M	272.0M
Non Current Liabilities Other	5.1M	5.3M	75.5M	51K	45.9K	43.6K
Long Term Debt Total	51.5M	51K	27.9M	28.2M	25.4M	28.3M
Net Invested Capital	(15.1M)	31.5M	21.9M	17.5M	53.8M	56.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Protalix Cash And Cash Equivalents Changes vs Begin Period Cash Flow Analysis

Cash And Cash Equivalents Changes vs Begin Period Cash Flow

Cash And Cash Equivalents Changes vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Cash And Cash Equivalents Changes

Begin Period Cash Flow

Protalix Biotherapeutics fundamental ratios Correlations

Protalix Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Protalix Biotherapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Protalix Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.98	Common Stock Total Equity
Property Plant And Equipment Net	+ 0.97	Non Current Assets Total
Total Current Assets	+ 0.96	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.95	Total Assets
Cash And Short Term Investments	+ 0.95	Cash

Other Stockholder Equity	- 0.79	Retained Earnings
Total Stockholder Equity	- 0.72	Total Liab
Other Stockholder Equity	- 0.72	Other Current Assets
Retained Earnings	- 0.7	Common Stock Shares Outstanding
Total Stockholder Equity	- 0.68	Non Current Liabilities Total
Total Current Assets	- 0.65	Other Current Assets